Comparing GE HealthCare Technologies (NASDAQ:GEHC) and Pro Medicus (OTCMKTS:PMCUF)

GE HealthCare Technologies (NASDAQ:GEHC) and Pro Medicus (OTCMKTS:PMCUF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for GE HealthCare Technologies and Pro Medicus, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0	5	6	1	2.67
Pro Medicus	0	0	0	0	N/A

GE HealthCare Technologies currently has a consensus price target of $95.00, indicating a potential upside of 13.19%. Given GE HealthCare Technologies’ higher possible upside, equities analysts plainly believe GE HealthCare Technologies is more favorable than Pro Medicus.

Institutional & Insider Ownership

82.1% of GE HealthCare Technologies shares are held by institutional investors. Comparatively, 10.8% of Pro Medicus shares are held by institutional investors. 0.3% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares GE HealthCare Technologies and Pro Medicus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	8.10%	25.26%	5.79%
Pro Medicus	N/A	N/A	N/A

Valuation and Earnings

This table compares GE HealthCare Technologies and Pro Medicus’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$19.52 billion	1.96	$1.57 billion	$3.42	24.54
Pro Medicus	N/A	N/A	N/A	$0.02	6,706.67

GE HealthCare Technologies has higher revenue and earnings than Pro Medicus. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Pro Medicus, indicating that it is currently the more affordable of the two stocks.

Dividends

GE HealthCare Technologies pays an annual dividend of $0.12 per share and has a dividend yield of 0.1%. Pro Medicus pays an annual dividend of $0.02 per share and has a dividend yield of 0.0%. GE HealthCare Technologies pays out 3.5% of its earnings in the form of a dividend. Pro Medicus pays out 133.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GE HealthCare Technologies is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

GE HealthCare Technologies beats Pro Medicus on 12 of the 13 factors compared between the two stocks.

About GE HealthCare Technologies

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women’s health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

About Pro Medicus

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other related health entities in Australia, North America, and Europe. The company offers Visage radiology information systems (RIS), a proprietary medical software for practice management, training, installation, professional services, and after-sale support and service products; and Promedicus.net, an e-health platform. It also provides healthcare imaging software that provides radiologists and clinicians with visualization capability for viewing 2-D, 3-D, and 4-D medical images, as well as picture archive and communication system (PACS)/digital imaging software; and integration products. In addition, the company offers Visage Ease Pro, a mobile application that provides users the ability to interpret various diagnostic imaging studies stored on a Visage 7 server. The company provides its products under the Visage RIS, Visage RIS/PACS, Visage 7, Visage Ease Pro, and Visage Ease names. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.